Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition

This article was originally published in The Tan Sheet

Executive Summary

FDA final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.


Related Content

ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns


Related Companies